Opendata, web and dolomites

NOTID

Novel treatment of inflammatory diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOTID project word cloud

Explore the words cloud of the NOTID project. It provides you a very rough idea of what is the project "NOTID" about.

leaders    achievement    immune    prevalence    intends    discovered    market    age    occurring    introduction    unable    co    woman    constituted    arthritis    patients    tnf    fill    enormous    biologicals    diagnosed    diseases    calculations    transient    orphan    suppress    lipum    frequently    biological    immunosuppressants    20    55    extreme    create    twice    lipase    strategy    salt    therapeutic    inflammatory    2014    85    responding    improvement    time    job    billion    poor    disability    quality    adverse    opinion    concluded    2019    ten    designation    countries    destruction    inhibitors    stimulated    mechanism    global    ra    treatment    disease    burden    hold    estimate    risk    economic    50    world    gap    idiopathic    directed    block    drug    alfa    complementary    drugs    joint    thereby    usd    serious    tentative    organisation    health    combined    antibody    societal    men    juvenile    onset    inhibit    pointed    rheumatoid    pharmaceuticals    full       children    total    life    bile    potentially    prevent   

Project "NOTID" data sheet

The following table provides information about the project.

Coordinator
LIPUM AB 

Organization address
address: TVISTEVAGEN 48 C
city: UMEA
postcode: 907 36
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.lipum.se
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIPUM AB SE (UMEA) coordinator 50˙000.00

Map

 Project objective

LipUm has discovered a novel treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases by a unique therapeutic antibody directed towards the Bile Salt-Stimulated Lipase, which has been identified as a key target to block and thereby inhibit the inflammatory process and prevent joint destruction. The global prevalence of RA is 0.3-1%, and it is twice as common among woman than men, and the risk to develop the condition increases by age. Frequently, other serious diseases are co-occurring with RA and according to the World Health Organisation 50% of patients in developed countries are unable to hold a full-time job within ten years after disease onset. The societal economic burden due to the disease is thus enormous, while health economic calculations estimate the cost for pharmaceuticals to less than 20% of the total cost. Still, the drug market value growth between 2014 and 2019 is expected to increase by 55% to 30 billion USD. The introduction and use of biologicals such as the TNF-alfa inhibitors constituted a major achievement in the treatment, but with time it has also been concluded that 1/3 of patients are not responding and another 1/3 experience only a transient improvement. As these biologicals suppress the immune system such drugs should not be combined with other immunosuppressants, as it may create adverse health effects. Key opinion leaders have therefore pointed out the need for drugs that have a complementary therapeutic mechanism. This is the gap that LipUm intends to fill and a tentative strategy is to apply for a orphan drug designation for juvenile idiopathic arthritis that affect children, frequently with extreme disability and poor quality of life. As an orphan drug our unique biological more rapidly could contribute to improved treatment of the 85,000 children diagnosed with the disease in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOTID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOTID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More